There are no randomized, placebo-controlled efficacy data in humans
A safer evidence ladder is: database identity, peer-reviewed pathway context, model-specific findings, analytical documentation, and supplier-specific batch records
BHUs GLP-1 friendly bars are the one bar that consistently hits the mark for people balancing diet, energy, and flavor
Regarding their metabolic effects, the combination of a GLP-1RA and a SGLT2i significantly reduces HbA1c level, body weight, and SBP, with an additive effect on weight loss and SBP but not on HbA1c [35, 57,58,59]
Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)